Literature DB >> 15120042

Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.

K Hansen1, C Khanna.   

Abstract

The preclinical development of anticancer drugs has been based primarily on the transplantation of murine or human cancers into mice. Alternatives to these transplantation models are animals that naturally develop cancers with features relevant to the human disease. The first group of these models arises in mice that are genetically engineered to develop cancer. The second group includes pet dogs and cats that naturally develop cancer. This review will discuss the use and integration of these spontaneous cancer models into a comprehensive and comparative approach to preclinical drug development. Examples of their successful use and an outline of their relative strengths and weaknesses will be provided.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15120042     DOI： 10.1016/j.ejca.2003.11.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  73 in total

1.  Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances.

Authors:  Hesed M Padilla-Nash; Karen Hathcock; Nicole E McNeil; David Mack; Daniel Hoeppner; Rea Ravin; Turid Knutsen; Raluca Yonescu; Danny Wangsa; Kathleen Dorritie; Linda Barenboim; Yue Hu; Thomas Ried
Journal:  Genes Chromosomes Cancer       Date:  2011-12-08       Impact factor: 5.006

2.  Development and characterization of 5 canine B-cell lymphoma cell lines.

Authors:  Allison L Zwingenberger; William Vernau; Changying Shi; Wensheng Yan; Xinbin Chen; Ira K Gordon; Michael S Kent
Journal:  Leuk Res       Date:  2011-12-01       Impact factor: 3.156

Review 3.  Defining the Value of a Comparative Approach to Cancer Drug Development.

Authors:  Amy K LeBlanc; Christina N Mazcko; Chand Khanna
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

4.  Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Authors:  Tyler J Bradshaw; Stephen Yip; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

5.  Graft function assessment in mouse models of single- and dual-kidney transplantation.

Authors:  Lei Wang; Ximing Wang; Shan Jiang; Jin Wei; Jacentha Buggs; Liying Fu; Jie Zhang; Ruisheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-23

6.  Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.

Authors:  Liliana M E Finocchiaro; Chiara Fondello; María L Gil-Cardeza; Úrsula A Rossi; Marcela S Villaverde; María D Riveros; Gerardo C Glikin
Journal:  Hum Gene Ther       Date:  2015-05-26       Impact factor: 5.695

7.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

8.  Copy number abnormalities in sporadic canine colorectal cancers.

Authors:  Jie Tang; Shoshona Le; Liang Sun; Xiuzhen Yan; Mucheng Zhang; Jennifer Macleod; Bruce Leroy; Nicole Northrup; Angela Ellis; Timothy J Yeatman; Yanchun Liang; Michael E Zwick; Shaying Zhao
Journal:  Genome Res       Date:  2010-01-19       Impact factor: 9.043

Review 9.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

10.  A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer.

Authors:  Dorothy Cimino Brown; Raymond Boston; James C Coyne; John T Farrar
Journal:  Pain Med       Date:  2008-09-24       Impact factor: 3.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.